🇺🇸 MS Contin in United States

FDA authorised MS Contin on 29 May 1987 · 115,100 US adverse-event reports

Marketing authorisation

FDA — authorised 29 May 1987

  • Application: NDA019516
  • Marketing authorisation holder: PURDUE PHARMA LP
  • Status: supplemented

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Dependence — 27,075 reports (23.52%)
  2. Overdose — 18,070 reports (15.7%)
  3. Pain — 14,855 reports (12.91%)
  4. Emotional Distress — 14,020 reports (12.18%)
  5. Death — 13,546 reports (11.77%)
  6. Drug Withdrawal Syndrome — 12,080 reports (10.5%)
  7. Toxicity To Various Agents — 9,399 reports (8.17%)
  8. Drug Abuse — 2,215 reports (1.92%)
  9. Drug Withdrawal Syndrome Neonatal — 2,061 reports (1.79%)
  10. Depression — 1,779 reports (1.55%)

Source database →

Other Pain Management approved in United States

Frequently asked questions

Is MS Contin approved in United States?

Yes. FDA authorised it on 29 May 1987.

Who is the marketing authorisation holder for MS Contin in United States?

PURDUE PHARMA LP holds the US marketing authorisation.